Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for Century Therapeutics in a research note issued to investors on Monday, May 19th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.37) per share for the quarter, down from their previous estimate of ($0.14). The consensus estimate for Century Therapeutics' current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.98) EPS and FY2029 earnings at ($0.87) EPS.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of ($0.31) by $1.20. The company had revenue of $109.16 million for the quarter, compared to the consensus estimate of $45.52 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%.

IPSC has been the subject of a number of other reports. Guggenheim reaffirmed a "buy" rating on shares of Century Therapeutics in a research note on Friday, March 28th. Piper Sandler lowered their price target on shares of Century Therapeutics from $4.00 to $2.00 and set an "overweight" rating for the company in a research report on Thursday, March 20th. Chardan Capital dropped their price objective on shares of Century Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, HC Wainwright cut their price objective on shares of Century Therapeutics from $5.00 to $2.00 and set a "buy" rating on the stock in a report on Thursday, April 3rd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics presently has an average rating of "Buy" and an average price target of $4.20.

Century Therapeutics Trading Down 2.7%

Shares of IPSC traded down $0.02 during midday trading on Wednesday, reaching $0.56. 426,222 shares of the stock were exchanged, compared to its average volume of 476,891. The company has a market capitalization of $48.15 million, a P/E ratio of -0.30 and a beta of 1.80. Century Therapeutics has a 52 week low of $0.34 and a 52 week high of $3.46. The company's 50 day moving average is $0.51 and its two-hundred day moving average is $0.83.

Institutional Trading of Century Therapeutics

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC grew its position in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock worth $133,000 after buying an additional 142,953 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Century Therapeutics by 26.9% in the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock valued at $86,000 after acquiring an additional 38,052 shares in the last quarter. AQR Capital Management LLC grew its holdings in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. Nuveen LLC purchased a new position in Century Therapeutics in the first quarter worth $75,000. Finally, Squarepoint Ops LLC increased its position in shares of Century Therapeutics by 56.0% during the fourth quarter. Squarepoint Ops LLC now owns 164,871 shares of the company's stock worth $167,000 after purchasing an additional 59,174 shares in the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.